29 January 2010
Nancy Faigen
The AIDS Healthcare Foundation (AHF), which operates clinics around the world including more than a dozen in the US, has ramped up its efforts to embarrass
Merck & Co over US pricing for the first HIV integrase inhibitor, Isentress (raltegravir), by banning Merck sales reps from its US...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: IOM focus on affordable 'essential' benefits expected to stir debate on drug prices
- Gilead's Truvada cut risk of HIV infection by up to 78% in heterosexuals
- Orexigen puts brakes on obesity program, blames 'unprecedented' CV demands from US FDA
- Positive PhIII data from Gilead's elvitegravir stands up at two years
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
